Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15393065 | 0.83 | HRH4 (0.48) | HRH4CHRNB2CHRNA4CSNK1ECHRNB4 | |
| SCHEMBL3431233 | 0.83 | HRH4 (0.52) | HRH4CHRNB2CHRNA4CSNK1E | |
| SCHEMBL3430563 | 0.76 | HRH4 (0.54) | HRH4CHRNB2CHRNA4CSNK1E | |
| SCHEMBL15392723 | 0.73 | CHRNB2 (0.52) | HRH4CHRNB2CHRNA4CSNK1ECHRNB4 | |
| SCHEMBL3433512 | 0.72 | CHRNB2 (0.51) | HRH4CHRNB2CHRNA4CSNK1ECHRNB4 | |
| SCHEMBL4514914 | 0.67 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL5786902 | 0.66 | ALDH1A1 (0.54) | HRH4CHRNB2CHRNA4CSNK1ECHRNB4 | |
| Hydrochloric Acid SCHEMBL5788832 | 0.65 | ALDH1A1 (0.52) | HRH4CHRNB2CHRNA4CSNK1ECHRNB4 | |
| SCHEMBL3433510 | 0.65 | HRH4 (0.52) | HRH4CHRNB2CHRNA4 | |
| SCHEMBL4785217 | 0.65 | CHRNA7 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2265607-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | Rigel Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009103032-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | PYGM, CKMT1A; CKMT1B, SMN1; SMN2 | HRH4 4318/4885CHRNB2 781/4885CHRNA4 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.